Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.45 |
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.40 |
| ▸ | ITGAV | P06756 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21683256 | 1.00 | CTSS (0.45) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL8484509 | 0.87 | CACNA1B (0.50) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL11337836 | 0.85 | CTSS (0.60) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL12029006 | 0.81 | KLK5 (0.55) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL18067866 | 0.81 | KLK5 (0.55) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL23924937 | 0.80 | GRB2 (0.43) | — | |
| SCHEMBL23924939 | 0.80 | GRB2 (0.43) | — | |
| SCHEMBL539770 | 0.78 | CTSS (0.55) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL539771 | 0.78 | CTSS (0.55) | CTSSCTSKCTSBCTSLITGB3 | |
| SCHEMBL21683250 | 0.77 | CTSS (0.50) | CTSSCTSKCTSBCTSLREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | UAB RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
| WO-2020033317-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | TGFBR2, SMAD2, TGFB2 | CTSS 1930/4885CTSK 2284/4885CTSB 1319/4885 |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | TGFBR2, SMAD2, TGFB2 | CTSS 1930/4885CTSK 2284/4885CTSB 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.